

US-India Chamber of Commerce Summit

The USA-India Chamber of Commerce (USAIC), a bilateral Chamber of Commerce, will organize its annual US-India BioPharma and Healthcare Summit on June 27 at the Marriott Cambridge, Massachusetts, USA.

USAIC's BioPharma and Healthcare Summit 2014 will bring together key stakeholders from industry, academia, investors, and government to engage in active debate and idea generation on routes for successful collaboration between global BioPharma companies, academia, and India's BioPharma industry and academia. McKinsey and Company is the Knowledge Partner. USAIC commissioned McKinsey and Company Position Paper will be released at the Summit.

The Summit will focus on BioPharma R&D strategy; specific discussions on Cardiovascular and Metabolic Diseases (Diabetes); Biologics and Biosimilars; Industry-Academic Partnerships; and Funding Innovation and M&A trends. Authors of the bestselling book "Reimagining India-Unlocking the Potential of Asia's Next Superpower" will participate in a panel discussion. Dr Robert Langer, Institute Professor, MIT, will address the summit. "India can learn a lot from Dr Langer's work in translational research," said Mr Karun Rishi, president of the USA India Chamber of Commerce.

Prof. K VijayRaghavan, Secretary, Department of Biotechnology (DBT) along with his colleagues is likely to participate.

"2014 so far has been a blockbuster for

Biotech IPOs. M&A activity has hit record high. We hope this will lead to increased R&D spend and subsequent launch of new life saving drugs," said Mr Rishi. "The new central government in India has brought hope and positive energy. Investor sentiments are bullish. Reimagining India panel at the summit is perfectly timed. It will help articulate India's potential to the global R&D, academic leaders, and investors," said Mr Karun Rishi.

Added Mr KV Subramaniam, chief executive officer of Reliance Life Sciences and USAIC Advisory Board member, "I have been associated with the US-India BioPharma and Healthcare Summit since the year 2009. During this period, I have seen the Summit graduate from being a bridge between US and India to share developments and perspectives in modern medicine to being a thought leader engaging with a wide range of constituencies in the industry and in a larger social context."

Mr Michael Rosenblatt, executive vice president, Merck & Co and USAIC Advisory Board member, commented, "We believe India has a strong potential to become a hub for biopharma innovation and play a leading role in collaborative research for the same. There is a need for enhanced partnerships between Indian innovators, government, and academia as well as their American counterparts in order to realize India's true potential as a bio-pharma hub. We congratulate the organizers for planning the US India BioPharma Summit which will provide a strong platform for dialogue on this important issue and to explore potential partnerships. **BS**



Mr Karun Rishi, president,
USA India Chamber of Commerce



Mr KV Subramaniam, CEO,
Reliance Life Sciences



Mr Martin Mackay, president,
Global R&D, Alexion



Mr Michael Rosenblatt,
executive vice president, Merck & Co



Dr Robert Langer,
Institute Professor, MIT